ProKidney Corp.
Bruce Culleton began their career as an Associate Professor at the University of Calgary, where they played a key role in establishing the Alberta Kidney Disease Network (AKDN). The network focused on various research initiatives related to kidney disease. Bruce then joined Baxter International Inc., where they served as Vice President for nearly nine years. Following their time at Baxter, they worked at Becton Dickinson as a World Wide Vice President, handling medical affairs and global clinical development. Bruce then held multiple positions at CVS Health, starting as Vice President and Chief Medical Officer of Kidney Care and later becoming Vice President and General Manager of CVS Kidney Care. Currently, they hold the role of Chief Executive Officer at ProKidney Corp. and was previously the Executive Vice President of Clinical Development and Commercialization at the same company.
Bruce Culleton earned a degree in Medicine, specializing in Nephrology, from Memorial University of Newfoundland between the years 1987 and 1997. Bruce then pursued a study of Epidemiology, specifically focusing on the Framingham Heart Study, at Boston University from 1997 to 1999. In 2009, Bruce obtained an MBA from Northwestern University's Kellogg School of Management.
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.